Leslie Trigg Sells 14,611 Shares of Outset Medical, Inc. (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 14,611 shares of Outset Medical stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $0.90, for a total transaction of $13,149.90. Following the completion of the transaction, the chief executive officer now owns 880,969 shares in the company, valued at $792,872.10. This trade represents a 1.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, January 21st, Leslie Trigg sold 65,236 shares of Outset Medical stock. The shares were sold at an average price of $0.80, for a total value of $52,188.80.
• On Monday, January 13th, Leslie Trigg sold 33,227 shares of Outset Medical stock. The stock was sold at an average price of $0.81, for a total value of $26,913.87.
• On Tuesday, January 7th, Leslie Trigg sold 10,227 shares of Outset Medical stock. The shares were sold at an average price of $1.29, for a total value of $13,192.83.

Outset Medical Stock Performance

Shares of NASDAQ OM traded up $0.03 during trading hours on Wednesday, reaching $0.94. The stock had a trading volume of 1,533,329 shares, compared to its average volume of 1,386,158. The company has a market cap of $50.48 million, a price-to-earnings ratio of -0.34 and a beta of 2.01. Outset Medical, Inc. has a twelve month low of $0.44 and a twelve month high of $5.22. The business’s fifty day moving average is $0.96 and its two-hundred day moving average is $0.85. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.49 and a quick ratio of 5.04.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Outset Medical had a negative net margin of 122.84% and a negative return on equity of 164.92%. As a group, research analysts expect that Outset Medical, Inc. will post -2.52 EPS for the current year.

Analyst Ratings Changes

Separately, Royal Bank of Canada reissued a “sector perform” rating and issued a $3.00 price objective on shares of Outset Medical in a research report on Tuesday, January 7th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new stake in shares of Outset Medical in the 4th quarter valued at approximately $174,000. Two Sigma Investments LP boosted its stake in Outset Medical by 36.0% in the 4th quarter. Two Sigma Investments LP now owns 488,602 shares of the company’s stock valued at $542,000 after buying an additional 129,334 shares in the last quarter. Birchview Capital LP grew its position in Outset Medical by 3,587.7% in the fourth quarter. Birchview Capital LP now owns 368,766 shares of the company’s stock valued at $409,000 after acquiring an additional 358,766 shares during the period. Two Sigma Securities LLC raised its stake in Outset Medical by 190.0% during the fourth quarter. Two Sigma Securities LLC now owns 42,477 shares of the company’s stock worth $47,000 after acquiring an additional 27,830 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Outset Medical during the fourth quarter worth $50,000.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.